Prognostic value of biomarkers related to drug resistance in patients with advanced epithelial ovarian cancer

Anticancer Research

Volumn 32, Issue 2, 2012, Pages 589-594

  Kim, Haeryoung ^a   Kim, Kidong ^a   No, Jae Hong ^a   Jeon, Yong Tark ^a   Jeon, Hye Won ^b   Kim, Yong Beom ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Ki 67 antigen; Multidrug resistance associated protein 2; Ovarian epithelial cancer; Ovarian neoplasm; Tissue microarrays

Indexed keywords

ABC TRANSPORTER A1; ATP BINDING CASSETTE TRANSPORTER C1; ATP BINDING CASSETTE TRANSPORTER C2; CARBOPLATIN; CYCLIN E; KI 67 ANTIGEN; PACLITAXEL; PROTEIN KINASE B BETA; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; HUMAN; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REGRESSION ANALYSIS; TISSUE MICROARRAY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84863171590     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Berek JS and Natarajan S: Ovarian and Fallopian Tube Cancer. In: Berek & Novak's Gynecology. Berek JS (eds.). Philadelphia; Lippincott Williams & Wilkins, pp. 1457-1547, 2007.
2. McGuire WP and Ozols RF: Chemotherapy of advanced ovarian cancer. Semin Oncol 25: 340-348, 1998. (Pubitemid 28272608)
3. Ozols RF: Update on the management of ovarian cancer. Cancer J 8(Suppl 1): S22-30, 2002.
4. Goff BA, Muntz HG, Greer BE, Tamimi HK and Gown AM: Oncogene expression: long-term compared with short-term survival in patients with advanced epithelial ovarian cancer. Obstet Gynecol 92: 88-93, 1998. (Pubitemid 28285327)
5. Kaern J, Aghmesheh M, Nesland JM, Danielsen HE, Sandstad B, Friedlander M and Trope C: Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors? Int J Gynecol Cancer 15: 1014-1022, 2005. (Pubitemid 43110149)
6. Garcia-Velasco A, Mendiola C, Sanchez-Munoz A, Ballestin C, Colomer R and Cortes-Funes H: Prognostic value of hormonal receptors, p53, Ki67 and HER2/neu expression in epithelial ovarian carcinoma. Clin Transl Oncol 10: 367-371, 2008.
7. Chen H, Hao J, Wang L and Li Y: Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer 101: 432-440, 2009.
8. Materna V, Pleger J, Hoffmann U and Lage H: RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 94: 152-160, 2004. (Pubitemid 38950512)
9. Ma JJ, Chen BL and Xin XY: Inhibition of multidrug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene. Arch Gynecol Obstet 279: 149-157, 2009.
10. Yadav S, van Vlerken LE, Little SR and Amiji MM: Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol 63: 711-722, 2009.
11. Farley J, Smith LM, Darcy KM, Sobel E, O'Connor D, Henderson B, Morrison LE and Birrer MJ: Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res 63: 1235-1241, 2003. (Pubitemid 36348700)
12. Rosen DG, Yang G, Deavers MT, Malpica A, Kavanagh JJ, Mills GB and Liu J: Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer 106: 1925-1932, 2006. (Pubitemid 43673207)
13. Sui L, Dong Y, Ohno M, Sugimoto K, Tai Y, Hando T and Tokuda M: Implication of malignancy and prognosis of p27(KIP1), cyclin E, and CDK2 expression in epithelial ovarian tumors. Gynecol Oncol 83: 56-63, 2001. (Pubitemid 32959879)
14. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Benedetti Panici P, Mancuso S, Neri G and Testa JR: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64: 280-285, 1995.
15. Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, Coppola D, Nicosia SV and Cheng JQ: Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/AKT pathway in human ovarian cancer. Oncogene 19: 2324-2330, 2000. (Pubitemid 30307208)
16. Yokoyama Y, Sato S, Fukushi Y, Sakamoto T, Futagami M and Saito Y: Significance of multidrug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res 25: 387-394, 1999. (Pubitemid 30028827)
17. Arts HJ, Katsaros D, de Vries EG, Massobrio M, Genta F, Danese S, Arisio R, Scheper RJ, Kool M, Scheffer GL, Willemsc PH, van der Zee AG and Suurmeijer AJ: Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res 5: 2798-2805, 1999. (Pubitemid 29493954)
18. Kritpracha K, Hanprasertpong J, Chandeying V, Dechsukhum C and Geater A: Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining. J Obstet Gynaecol Res 31: 268-276, 2005. (Pubitemid 40943740)
19. Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Konsgen D, Lage H, Noske A, Weichert W, Buckendahl AC, Budczies J, Muller BM, Elwali NE, Dietel M and Denkert C: Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: implication for prognosis. Histopathology 54: 657-666, 2009.
20. Musgrove EA: Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors 24: 13-19, 2006.